References
- King TE Jr, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet378(9807), 1949–1961 (2011).
- Navaratnam V , FlemingKM, WestJet al. The rising incidence of idiopathic pulmonary fibrosis in the U.K. Thorax 66(6), 462–467 (2011).
- Cottin V . Changing the idiopathic pulmonary fibrosis treatment approach and improving patient outcomes. Eur. Respir. Rev.21(124), 161–167 (2012).
- Adamali HI , MaherTM. Current and novel drug therapies for idiopathic pulmonary fibrosis. Drug Des. Devel. Ther.6, 261–272 (2012).
- Iyer SN , GurujeyalakshmiG, GiriSN. Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J. Pharmacol. Exp. Ther.291(1), 367–373 (1999).
- Lasky J . Pirfenidone. IDrugs7(2), 166–172 (2004).
- Schaefer CJ , RuhrmundDW, PanL, SeiwertSD, KossenK. Antifibrotic activities of pirfenidone in animal models. Eur. Respir. Rev.20(120), 85–97 (2011).
- Macias-Barragan J , Sandoval-RodriguezA, Navarro-PartidaJ, Armendariz-BorundaJ. The multifaceted role of pirfenidone and its novel targets. Fibrogenesis Tissue Repair3, 16 (2010).
- Richeldi L , YasothanU, KirkpatrickP. Pirfenidone. Nat. Rev. Drug Discov.10(7), 489–490 (2011).
- Taniguchi H , EbinaM, KondohYet al. Pirfenidone in idiopathic pulmonary fibrosis. Eur. Respir. J. 35(4), 821–829 (2010).
- Hilberg O , SimonsenU, Du Bois R, Bendstrup E. Pirfenidone: significant treatment effects in idiopathic pulmonary fibrosis. Clin. Respir. J.6(3), 131–143 (2012).
- Carter NJ . Pirfenidone: in idiopathic pulmonary fibrosis. Drugs71(13), 1721–1732 (2011).
- Onoue S , SetoY, GandyG, YamadaS. Drug-induced phototoxicity; an early in vitro identification of phototoxic potential of new drug entities in drug discovery and development. Curr. Drug Saf.4(2), 123–136 (2009).
- Epstein JH , WintroubBU. Photosensitivity due to drugs. Drugs30(1), 42–57 (1985).
- Seto Y , InoueR, KatoM, YamadaS, OnoueS. Photosafety assessments on pirfenidone: photochemical, photobiological, and pharmacokinetic characterization. J. Photochem. Photobiol. B.120, 44–51 (2013).
- Seto Y , InoueR, OchiM, GandyG, YamadaS, OnoueS. Combined use of in vitro phototoxic assessments and cassette dosing pharmacokinetic study for phototoxicity characterization of fluoroquinolones. AAPS J.13(3), 482–492 (2011).
- Onoue S , AokiY, KawabataYet al. Development of inhalable nanocrystalline solid dispersion of tranilast for airway inflammatory diseases. J. Pharm. Sci. 100(2), 622–633 (2011).
- Onoue S , SatoH, KawabataY, MizumotoT, HashimotoN, YamadaS. In vitro and in vivo characterization on amorphous solid dispersion of cyclosporine A for inhalation therapy. J. Control. Release138, 16–23 (2009).
- Trivedi R , RedenteEF, ThakurA, RichesDW, KompellaUB. Local delivery of biodegradable pirfenidone nanoparticles ameliorates bleomycin-induced pulmonary fibrosis in mice. Nanotechnology23(50), 505101 (2012).
- Onoue S , SetoY, KatoM, AokiY, KojoY, YamadaS. Inhalable powder formulation of pirfenidone with reduced phototoxic risk for treatment of pulmonary fibrosis. Pharm. Res.30(6), 1586–1596 (2013).